| Autor: |
Ghosh I; Sterile Product Development, Bristol Myers Squibb, New Brunswick, NJ, USA., Gutka H; Sterile Product Development, Bristol Myers Squibb, New Brunswick, NJ, USA., Krause ME; Sterile Product Development, Bristol Myers Squibb, New Brunswick, NJ, USA., Clemens R; College of Pharmacy, University of Illinois at Chicago, Chicago, USA., Kashi RS; Sterile Product Development, Bristol Myers Squibb, Summit, NJ, USA. |
| Abstrakt: |
Three critical aspects that define high concentration antibody products (HCAPs) are as follows: 1) formulation composition, 2) dosage form, and 3) primary packaging configuration. HCAPs have become successful in the therapeutic sector due to their unique advantage of allowing subcutaneous self-administration. Technical challenges, such as physical and chemical instability, viscosity, delivery volume limitations, and product immunogenicity, can hinder successful development and commercialization of HCAPs. Such challenges can be overcome by robust formulation and process development strategies, as well as rational selection of excipients and packaging components. We compiled and analyzed data from US Food and Drug Administration-approved and marketed HCAPs that are ≥100 mg/mL to identify trends in formulation composition and quality target product profile. This review presents our findings and discusses novel formulation and processing technologies that enable the development of improved HCAPs at ≥200 mg/mL. The observed trends can be used as a guide for further advancements in the development of HCAPs as more complex antibody-based modalities enter biologics product development. |
